Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000947871-24-001018
Filing Date
2024-12-18
Accepted
2024-12-18 17:20:21
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6116
2 ITEM 7 INFORMATION ss4260211_ex9901.htm EX-99.1 3801
3 CERTIFICATE OF INCUMBENCY ss4260211_ex9902.htm EX-99.2 4812
  Complete submission text file 0000947871-24-001018.txt   16373
Mailing Address P.O. BOX 23224 DOHA S3 QATAR
Business Address OOREDOO TOWER (BUILDING 14), AL DAFNA ST (STREET 801) DOHA S3 QATAR 974 441 4466
Qatar Investment Authority (Filed by) CIK: 0001441449 (see all company filings)

EIN.: 000000000 | State of Incorp.: S3 | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Subject) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90437 | Film No.: 241560285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)